Median, 2-, 5-, and 10-year (predicted) overall survivals
| Characteristic . | n . | Median survival, mo . | 2 years, % . | 5 years, % . | 10 years, % . |
|---|---|---|---|---|---|
| Estimated overall survival (entire cohort) | |||||
| From diagnosis of advanced-stage disease | 92 | 60 | 65.8 | 48.9 | 31.8 |
| Clinical stage (P < .003) | |||||
| Stage IIB | 42 | 36 | 61.0 | 39.4 | 23.4 |
| Stage III | 36 | 132 | 83.9 | 67.8 | 53.9 |
| Stages IVA and IVB | 12 | 14.5 | 25 | 12.5 | — |
| Tumor (T) stage (P = .01) | |||||
| Patch/plaque (T2) | 7 | 8 | 42.9 | 21.4 | — |
| Tumor (T3) | 46 | 29 | 55.7 | 36.7 | 21.8 |
| Erythroderma (T4) | 39 | 132 | 82.9 | 65.2 | 52.3 |
| Presentation (P = .25) | |||||
| Advanced-stage de novo | 62 | 61 | 72.3 | 53.0 | 32.1 |
| Progression from early-stage | 30 | 36 | 51.9 | 41.5 | 34.6 |
| Age at initial diagnosis (P = .01) | |||||
| 60 y or older | 47 | 72 | 75.1 | 57.4 | 26.1 |
| Younger than 60 y | 45 | 144 | 86.1 | 72.5 | 55.9 |
| Large cell transformation (P = .17) | |||||
| No transformation | 70 | 62 | 70.7 | 53.6 | 34.0 |
| Transformation | 22 | 27 | 50.6 | 32.5 | — |
| CD30 large cell expression (P = .19) | |||||
| CD30-positive large cells | 9 | 57 | 55.6 | 41.7 | — |
| CD30-negative large cells | 13 | 27 | 51.9 | — | — |
| Erythrodermic disease (P = .34) | |||||
| Sézary syndrome | 31 | 132 | 75.0 | 60.8 | 54.7 |
| Erythrodermic mycosis fungoides | 8 | 96 | 100.0 | 50.0 | — |
| Characteristic . | n . | Median survival, mo . | 2 years, % . | 5 years, % . | 10 years, % . |
|---|---|---|---|---|---|
| Estimated overall survival (entire cohort) | |||||
| From diagnosis of advanced-stage disease | 92 | 60 | 65.8 | 48.9 | 31.8 |
| Clinical stage (P < .003) | |||||
| Stage IIB | 42 | 36 | 61.0 | 39.4 | 23.4 |
| Stage III | 36 | 132 | 83.9 | 67.8 | 53.9 |
| Stages IVA and IVB | 12 | 14.5 | 25 | 12.5 | — |
| Tumor (T) stage (P = .01) | |||||
| Patch/plaque (T2) | 7 | 8 | 42.9 | 21.4 | — |
| Tumor (T3) | 46 | 29 | 55.7 | 36.7 | 21.8 |
| Erythroderma (T4) | 39 | 132 | 82.9 | 65.2 | 52.3 |
| Presentation (P = .25) | |||||
| Advanced-stage de novo | 62 | 61 | 72.3 | 53.0 | 32.1 |
| Progression from early-stage | 30 | 36 | 51.9 | 41.5 | 34.6 |
| Age at initial diagnosis (P = .01) | |||||
| 60 y or older | 47 | 72 | 75.1 | 57.4 | 26.1 |
| Younger than 60 y | 45 | 144 | 86.1 | 72.5 | 55.9 |
| Large cell transformation (P = .17) | |||||
| No transformation | 70 | 62 | 70.7 | 53.6 | 34.0 |
| Transformation | 22 | 27 | 50.6 | 32.5 | — |
| CD30 large cell expression (P = .19) | |||||
| CD30-positive large cells | 9 | 57 | 55.6 | 41.7 | — |
| CD30-negative large cells | 13 | 27 | 51.9 | — | — |
| Erythrodermic disease (P = .34) | |||||
| Sézary syndrome | 31 | 132 | 75.0 | 60.8 | 54.7 |
| Erythrodermic mycosis fungoides | 8 | 96 | 100.0 | 50.0 | — |
— indicates not applicable.